The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | 7-year follow-up of ibrutinib monotherapy for R/R and first-line CLL
The safety and efficacy of single-agent ibrutinib was investigated in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in the first-line and relapsed/refractory settings. In this interview, Susan O’Brien, MD, of the University of California, Irvine, CA, discusses the data from the longest follow-up available, up to 7-years, from the Phase Ib/II PCYC-1102 trial (NCT01105247), and PCYC-1103 extension study (NCT01109069). Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. O’Brien reveals the sustained activity of single-agent ibrutinib, including in those with high-risk genomic factors, with the addition of no new safety signals or late toxicities.
